secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2022-02-16T23:59:59+00:00
Accession:  0001104659-22-024083
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone Pharmaceuticals appoints Dr. David Bharucha as CMO; grants 330,000 option inducement award
--------------------------------------------------------------------------------

- Appointed Dr. David Bharucha as CMO effective Feb 15, 2022.
- Granted inducement option to purchase 330,000 common shares vesting over 4 years.
- Base salary $445,000 and target annual bonus of 40% of base salary.
- Prior CMO Francis Plat becomes Chief Scientific Officer; advisory role after RAPID trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922024083/0001104659-22-024083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922024083/tm226897d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-024083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer